Cargando…
DOACs and “newer” hemophilia therapies in COVID‐19: Reply
Autores principales: | Thachil, Jecko, Tang, Ning, Gando, Satoshi, Falanga, Anna, Cattaneo, Marco, Levi, Marcel, Clark, Cary, Iba, Toshiaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9770941/ https://www.ncbi.nlm.nih.gov/pubmed/32282993 http://dx.doi.org/10.1111/jth.14841 |
Ejemplares similares
-
Type and dose of heparin in Covid‐19: Reply
por: Thachil, Jecko, et al.
Publicado: (2020) -
ISTH interim guidance on recognition and management of coagulopathy in COVID‐19
por: Thachil, Jecko, et al.
Publicado: (2020) -
The application of anticoagulant therapy to sepsis
por: Thachil, Jecko, et al.
Publicado: (2017) -
Coagulation abnormalities and thrombosis in patients with COVID-19
por: Levi, Marcel, et al.
Publicado: (2020) -
Clinical significance of measuring plasminogen activator inhibitor-1 in sepsis
por: Iba, Toshiaki, et al.
Publicado: (2017)